Detalles de la búsqueda
1.
Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study.
Antimicrob Agents Chemother
; 63(4)2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30670416
2.
Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis.
Antimicrob Agents Chemother
; 60(1): 278-87, 2016 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26503648
3.
Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.
J Antimicrob Chemother
; 71(8): 2234-40, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27121401
4.
Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.
Antimicrob Agents Chemother
; 59(5): 2735-45, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25712363
5.
Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients.
J Infect Dis
; 208(2): 351-61, 2013 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23599314
6.
In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.
Antimicrob Agents Chemother
; 57(11): 5778-80, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24041890
7.
Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.
Antimicrob Agents Chemother
; 57(6): 2793-800, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23571544
8.
Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.
J Infect Dis
; 206(3): 442-52, 2012 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22634880
9.
Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Antimicrob Agents Chemother
; 56(5): 2435-42, 2012 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-22354305
10.
Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens.
Antimicrob Agents Chemother
; 56(10): 5303-8, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22869566
11.
Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Antimicrob Agents Chemother
; 56(10): 5180-5, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22825124
12.
Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach.
Antimicrob Agents Chemother
; 56(2): 708-14, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22123680
13.
Pharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.
Antimicrob Agents Chemother
; 56(8): 4146-53, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22615280
14.
Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.
J Infect Dis
; 203(9): 1324-32, 2011 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21357943
15.
Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Antimicrob Agents Chemother
; 55(10): 4880-7, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21807969
16.
Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.
Antimicrob Agents Chemother
; 54(8): 3432-41, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20439615
17.
Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days.
mBio
; 5(1): e00725-13, 2014 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-24473125
Resultados
1 -
17
de 17
1
Próxima >
>>